A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites

Inclusion Criteria: * Persistent or symptomatic ascites with positive cytology secondary to any histologically confirmed tumor type not amenable to cytoreductive surgery or additional chemotherapy * Patients may enroll in this study irrespective of previous therapy including diuretics, surgery, chemotherapy, immunotherapy and radiation therapy * Must have received a minimum of two paracentesis procedures and a trial of diuretic therapy within 60 days of study entry * Age Restrictions: 18-75 years * Life Expectancy: 12 weeks or more * ECOG Performance Status: 0-2 * Able and willing to provide informed consent and comply with study and/or follow-up procedures * Normal organ and marrow function as defined by: Leukocytes \>/= 3,000/mcL; Absolute neutrophil count \>/= 1,500/mcL; Platelets \>/= 100,000/mcL; Total bilirubin within normal institutional limits; AST (SGOT)/ALT(SGPT) \</= 2.5 X institutional upper limit of normal (ULN); Creatinine within normal institutional limits OR Creatinine clearance \>/+ 60 mL/min for patients with creatinine levels above the institutional normal; Serum Potassium within normal institutional limits; Serum Sodium within normal institutional limits Exclusion Criteria: * Patients having received anti-angiogenic agents as part of the treatment of their malignancy within 60 days prior to study entry * Current, recent (within 30 days of the first infusion of this study) or planned administration of chemotherapy (including all routes of administration)…